Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
M. Angela Aznar, Nicola Tinari, Antonio Rullan, et al.
The Journal of Immunology (2016) Vol. 198, Iss. 1, pp. 31-39
Open Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1183
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 926
Cancer nanomedicine for combination cancer immunotherapy
Jutaek Nam, Sejin Son, Kyong Soo Park, et al.
Nature Reviews Materials (2019) Vol. 4, Iss. 6, pp. 398-414
Closed Access | Times Cited: 809
Enhancing cancer immunotherapy with nanomedicine
Darrell J. Irvine, Eric L. Dane
Nature reviews. Immunology (2020) Vol. 20, Iss. 5, pp. 321-334
Open Access | Times Cited: 670
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester, Miguel F. Sanmamed, Jun Wang, et al.
Blood (2017) Vol. 131, Iss. 1, pp. 49-57
Open Access | Times Cited: 420
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Ignacio Melero, Eduardo Castañón, Maite Álvarez, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 558-576
Open Access | Times Cited: 341
Intratumoral immunotherapy: using the tumor as the remedy
Aurélien Marabelle, Lambros Tselikas, Thierry de Baère, et al.
Annals of Oncology (2017) Vol. 28, pp. xii33-xii43
Open Access | Times Cited: 306
Delivering safer immunotherapies for cancer
Lauren E. Milling, Yuan Zhang, Darrell J. Irvine
Advanced Drug Delivery Reviews (2017) Vol. 114, pp. 79-101
Open Access | Times Cited: 273
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 235
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Susannah L. Hewitt, Ailin Bai, D. R. Shackleton Bailey, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 477
Open Access | Times Cited: 234
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Alfonso R. Sánchez-Paulete, Álvaro Teijeira, Francisco J. Cueto, et al.
Annals of Oncology (2017) Vol. 28, pp. xii44-xii55
Open Access | Times Cited: 230
Macroscale biomaterials strategies for local immunomodulation
Maxence O. Dellacherie, Bo Ri Seo, David Mooney
Nature Reviews Materials (2019) Vol. 4, Iss. 6, pp. 379-397
Closed Access | Times Cited: 219
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Hanne Locy, Sven de Mey, Wout de Mey, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 213
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 1033-1033
Open Access | Times Cited: 191
Phase I Trial of Intratumoral Injection ofCCL21Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration
Jay M. Lee, Mi-Heon Lee, Edward B. Garon, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 16, pp. 4556-4568
Open Access | Times Cited: 184
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington, et al.
Annals of Oncology (2018) Vol. 29, Iss. 11, pp. 2163-2174
Open Access | Times Cited: 178
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity
Yingzhong Li, Zhijun Su, Weiyu Zhao, et al.
Nature Cancer (2020) Vol. 1, Iss. 9, pp. 882-893
Open Access | Times Cited: 178
Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery
Joke Deprez, Guillaume Lajoinie, Y. Engelen, et al.
Advanced Drug Delivery Reviews (2021) Vol. 172, pp. 9-36
Open Access | Times Cited: 156
Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy
Xueguang Lu, Lei Miao, Wenting Gao, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 556
Open Access | Times Cited: 152
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Qiang Lü, Dongquan Kou, Shenghan Lou, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 131
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani, Jeremiah A. Johnson, Darrell J. Irvine
Advanced Drug Delivery Reviews (2021) Vol. 175, pp. 113803-113803
Open Access | Times Cited: 124
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Yash Agarwal, Lauren E. Milling, Jason Y.H. Chang, et al.
Nature Biomedical Engineering (2022) Vol. 6, Iss. 2, pp. 129-143
Open Access | Times Cited: 96
CD8+ T cell exhaustion and cancer immunotherapy
Qingda Wang, Yang Qin, Bo Li
Cancer Letters (2022) Vol. 559, pp. 216043-216043
Closed Access | Times Cited: 74
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 54
Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Lutz Nuhn, Stefaan De Koker, Sandra Van Lint, et al.
Advanced Materials (2018) Vol. 30, Iss. 45
Closed Access | Times Cited: 140
Page 1 - Next Page

Scroll to top